Advertisement
Advanced searchCitation search
Skip main navigation
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Advertisement
No AccessJournal of UrologyUrological Survey1 Jan 2020

Re: Evaluation of Axitinib to Downstage cT2a Renal Tumours and Allow Partial Nephrectomy: A Phase II Study

    View All Author Information
    https://doi.org/10.1097/01.JU.0000604416.53744.70
    "Re: Evaluation of Axitinib to Downstage cT2a Renal Tumours and Allow Partial Nephrectomy: A Phase II Study." The Journal of Urology, 203(1), pp. 28–29

    Suggested Reading

    • : Renal mass and localized renal cancer: AUA guideline. J Urol 2017; 198: 520. Link, Google Scholar
    • : Outcome of stage T2 or greater renal cell cancer treated with partial nephrectomy. J Urol 2010; 183: 903. Link, Google Scholar
    • : Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 2009; 181: 518. Link, Google Scholar
    • : Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol 2001; 166: 6. Link, Google Scholar
    • : A phase II study of pazopanib in patients with localized renal cell carcinoma to optimize preservation of renal parenchyma. J Urol 2015; 194: 297. Link, Google Scholar
    • : The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J Urol 2012; 187: 1548. Link, Google Scholar
    © 2020 by American Urological Association Education and Research, Inc.
    Copyright © 2025 American Urological Association Education and Research, Inc.

    COPYRIGHT AND PERMISSIONS: The Journal of Urology® is the Official Journal of the American Urological Association Education and Research, Inc. and is published monthly by Wolters Kluwer Health Inc. The American Urological Association grants the Publisher full and exclusive publishing and distribution rights, worldwide, for both print and electronic media. Therefore no portions of the work(s) can be reproduced without written consent from the Publisher. Permissions and photocopying: For permission and/or rights to use content for which the copyright holder is Wolters Kluwer or the society we have partnered with the Copyright Clearance Center to provide permissions for our products through their RightsLink service, please go to the journal's website and after clicking on the relevant article, click on the Get Content & Permissions link under the Article Tools box that appears on the right side of the page. For questions about the Rightslink service, e-mail [email protected] or call 877-622-5543 (U.S. Only) or 978-777-9929. Permissions FAQs and information on authors permission requests are available at Journal Permission.

    For translation rights requests, contact Translations. For license to republish and distribute requests, contact Licensing. For special projects and reprints (U.S./Canada), contact Alan Moore or [email protected]. For special projects and reprints (non-U.S./Canada), contact Avia Potashnik at [email protected] or [email protected].

    PRIVACY POLICY: This page is operated by Wolters Kluwer and is subject to Wolters Kluwer Privacy Policy.
    Your California Privacy Choicesopt-out icon